Cite
Peeters SA, Engelen L, Buijs J, et al. Erratum to: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovasc Diabetol. 2015;14:128doi: 10.1186/s12933-015-0290-4.
Peeters, S. A., Engelen, L., Buijs, J., Chaturvedi, N., Fuller, J. H., Schalkwijk, C. G., Stehouwer, C. D. (2015). Erratum to: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovascular diabetology, 14128. https://doi.org/10.1186/s12933-015-0290-4
Peeters, Stijn A, et al. "Erratum to: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study." Cardiovascular diabetology vol. 14 (2015): 128. doi: https://doi.org/10.1186/s12933-015-0290-4
Peeters SA, Engelen L, Buijs J, Chaturvedi N, Fuller JH, Schalkwijk CG, Stehouwer CD. Erratum to: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovasc Diabetol. 2015 Sep 28;14:128. doi: 10.1186/s12933-015-0290-4. PMID: 26415611; PMCID: PMC4587827.
Copy
Download .nbib